Ademuyiwa FO et al. Prognostic Factors in Stage III non-small-cell lung cancer. Clin Lung Cancer. 2007;8(8):478-82. Abstract

Gandara DR et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21(10):2004-10. Abstract

Giorgio CG et al. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Anticancer Drugs. 2007;18(6):713-9. Abstract

Hanna NH et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Proc ASCO 2007;Abstract 7512.

Heymach JV et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007;25(27):4270-7. Abstract

Hirsch V et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007;2(10):927-32. Abstract

Kelly K et al. Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. Proc ASCO 2007;Abstract 7513.

Milleron B et al. IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results. Proc ASCO 2007;Abstract 7519.

Robinson, LA et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):243S-265S. Abstract

Sirohi B et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol. 2007;2(8):735-40. Abstract

Syrigos KN et al. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res. 2007;27(4C):2887-92. Abstract